share_log

Citigroup | 424B8: Prospectus

Citigroup | 424B8: Prospectus

花旗集團 | 424B8:募資說明書
美股SEC公告 ·  11/07 19:09

Moomoo AI 已提取核心訊息

Citigroup Global Markets Holdings Inc., a subsidiary of Citigroup Inc., has issued a new series of unsecured senior debt securities, known as Medium-Term Senior Notes, Series N. These securities, referred to as Autocallable Phoenix Securities, are based on the SPDR S&P Biotech ETF and are due on November 7, 2025. The securities are designed to offer potential for contingent coupon payments at an annualized rate that could yield higher than Citigroup's conventional debt securities of the same maturity. However, they carry risks including the possibility of receiving no contingent coupon payments, receiving less than the principal amount at maturity, or automatic redemption prior to maturity. The securities are linked to the performance of the SPDR S&P Biotech ETF...Show More
Citigroup Global Markets Holdings Inc., a subsidiary of Citigroup Inc., has issued a new series of unsecured senior debt securities, known as Medium-Term Senior Notes, Series N. These securities, referred to as Autocallable Phoenix Securities, are based on the SPDR S&P Biotech ETF and are due on November 7, 2025. The securities are designed to offer potential for contingent coupon payments at an annualized rate that could yield higher than Citigroup's conventional debt securities of the same maturity. However, they carry risks including the possibility of receiving no contingent coupon payments, receiving less than the principal amount at maturity, or automatic redemption prior to maturity. The securities are linked to the performance of the SPDR S&P Biotech ETF, and investors will not benefit from any appreciation of the ETF or receive dividends from it. The total aggregate principal amount of the securities is $11,000,000, with each security having a stated principal amount of $1,000. The securities were priced on November 4, 2024, and issued on November 7, 2024, with Citigroup Inc. fully and unconditionally guaranteeing all payments. The securities are not listed on any securities exchange, and Citigroup Global Markets Inc., an affiliate of the issuer, is the underwriter. Investors are warned of the credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc., and the potential illiquidity of the investment.
花旗集團全球市場控股公司(Citigroup Global Markets Holdings Inc.)是花旗銀行的子公司,已發行一系列新的無抵押優先債務證券,稱爲中期優先票據,N系列。這些證券,被稱爲可自動贖回鳳凰證券,基於SPDR標普生物科技etf,到期日爲2025年11月7日。這些證券旨在提供對條件性票據支付的潛在機會,其年化利率可能高於花旗銀行相同到期日的傳統債務證券。然而,它們包含風險,包括可能不會收到條件性票據支付、在到期時收到少於本金金額,或在到期前自動兌付。這些證券與SPDR標普生物科技etf的表現相關聯,投資者將不受益於etf的升值或獲得其分紅。這些證券的總計本金金額爲110...展開全部
花旗集團全球市場控股公司(Citigroup Global Markets Holdings Inc.)是花旗銀行的子公司,已發行一系列新的無抵押優先債務證券,稱爲中期優先票據,N系列。這些證券,被稱爲可自動贖回鳳凰證券,基於SPDR標普生物科技etf,到期日爲2025年11月7日。這些證券旨在提供對條件性票據支付的潛在機會,其年化利率可能高於花旗銀行相同到期日的傳統債務證券。然而,它們包含風險,包括可能不會收到條件性票據支付、在到期時收到少於本金金額,或在到期前自動兌付。這些證券與SPDR標普生物科技etf的表現相關聯,投資者將不受益於etf的升值或獲得其分紅。這些證券的總計本金金額爲1100萬美元,每個證券的標明本金金額爲1000美元。這些證券定價於2024年11月4日,並於2024年11月7日發行,由花旗銀行全額無條件擔保所有支付。這些證券未在任何證券交易所上市,而發行人的附屬公司花旗全球市場公司(Citigroup Global Markets Inc.)是承銷商。投資者被警告花旗集團全球市場控股公司和花旗銀行的信貸風險,以及投資可能的流動性不足。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息